A phase Ib trial studied combination magrolimab (5F9), a first-in-class anti-CD47 antibody, and AZA in adults with newly diagnosed AML who are unfit for intensive chemotherapy and high-risk MDS patients [84]. This evidence concerns the gene CD47 and myelodysplastic syndrome.